Quick Answer
Corvus Pharmaceuticals, Inc. reported R&D Expense of $33.72 million for fiscal year 2025.
Corvus Pharmaceuticals, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $33.72M | +73.9% |
| 2024 | $19.39M | +17.3% |
| 2023 | $16.53M | -32.5% |
| 2022 | $24.47M | -16.0% |
| 2021 | $29.11M | -8.5% |
| 2020 | $31.83M | -16.2% |
| 2019 | $37.98M | -1.6% |
| 2018 | $38.59M | -16.7% |
| 2017 | $46.30M | +57.7% |
| 2016 | $29.36M | +158.6% |
| 2015 | $11.35M | +29773.7% |
| 2014 | $38.0K | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $8.45M | +61.9% | +7.4% |
| June 30, 2025 | $7.87M | +91.4% | +5.6% |
| March 31, 2025 | $7.45M | +82.9% | +42.7% |
| September 30, 2024 | $5.22M | +31.7% | +26.9% |
| June 30, 2024 | $4.11M | +3.7% | +1.0% |
| March 31, 2024 | $4.08M | -11.3% | +2.8% |
| September 30, 2023 | $3.96M | -61.7% | -0.1% |
| June 30, 2023 | $3.97M | -19.4% | -13.6% |
- Corvus Pharmaceuticals, Inc. showed an increase of +73.9% in R&D Expense compared to the prior fiscal year.
- Over the 2014–2025 period, Corvus Pharmaceuticals, Inc.’s r&d expense has grown by 88634.2% (from $38.0 thousand to $33.72 million).
- The most recent figure is from Corvus Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: